ASCO 2026: Discover the Latest Breakthroughs and Clinical Insights
- Home
- asco conference 2026
- asco 2026 latest breakthroughs
ASCO 2026 Latest Breakthroughs
ASCO 2026: Discover the Latest Breakthroughs and Clinical Insights
The American Society of Clinical Oncology (ASCO) Annual Meeting is the world's largest oncology congress; it takes place every late May–early June in Chicago at the McCormick Place convention center, with over 40,000 delegates. The ASCO 2026 Annual Meeting is expected to showcase several practice-changing clinical data readouts, particularly during the Plenary Sessions, which highlight the most impactful oncology advancements. Scheduled from May 29 to June 2, 2026, the meeting will feature major updates across multiple tumor types, with a strong focus on pancreatic cancer, non-small cell lung cancer (NSCLC), and skin melanoma. Leading companies, including Revolution Medicines, Pfizer, Akeso, and AstraZeneca and others, are anticipated to present pivotal Phase III and late-stage clinical data that could significantly influence future treatment landscapes and clinical practice.
ASCO's annual plenary session features the congress's "showcase" studies. This year's five selected Late-Breaking Abstracts (LBAs) represent all five main axes of modern oncology: perioperative intensification, biology-driven drug repositioning in rare tumors, targeted adjuvant therapy, next-generation immunotherapy, and direct RAS inhibition.
|
Delves into the latest buzz | ||||||
|
Company/University |
Drug Name |
Session |
Phase |
Abstract ID |
Indications |
Date |
|
Daraxonrasib |
Plenary Session |
Phase III |
LBA5 |
Previously treated metastatic pancreatic adenocarcinoma (mPDAC) |
31st May 2026 |
|
|
Tafasitamab + Lenalidomide and R-CHOP |
Oral Abstract Session |
Phase III |
LBA7000 |
Hematologic Malignancies -- newly diagnosed diffuse large B-cell lymphoma (DLBCL) |
30th May 2026 |
|
|
Bezuclastinib + Sunitinib |
Oral Abstract Session |
Phase III |
11500 |
Advanced gastrointestinal stromal tumors (GIST) |
30th May 2026 |
|
|
Glofitamab |
Oral Abstract Session |
Phase III |
7006 |
Hematologic Malignancies -- relapsed/refractory (R/R) mantle cell lymphoma with/without prior BTKi exposure |
30th May 2026 |
|
|
Mosunetuzumab + Polatuzumab vedotin |
Oral Abstract Session |
Phase III |
7007 |
Hematologic Malignancies -- relapsed/refractory large B-cell lymphoma (R/R LBCL) |
30th May 2026 |
|
|
Pembrolizumab |
Oral Abstract Session |
Phase III |
507 |
Breast Cancer -- high-risk early-stage TNBC |
30th May 2026 |
|
|
Talazoparib + enzalutamide |
Oral Abstract Session |
Phase III |
LBA5007 |
Genitourinary Cancer -- mCSPC harboring homologous recombination repair (HRR) gene alterations |
30th May 2026 |
|
|
Mosunetuzumab + Polatuzumab vedotin |
Oral Abstract Session |
Phase III |
7007 |
Hematologic Malignancies -- relapsed/refractory large B-cell lymphoma (R/R LBCL) |
30th May 2026 |
|
|
Fuzuloparib + abiraterone acetate and prednisone |
Oral Abstract Session |
Phase III |
5008 |
Genitourinary Cancer -- metastatic castration-resistant prostate cancer (mCRPC) |
30th May 2026 |
|
|
Epcoritamab +rituximab-mini CVP |
Oral Abstract Session |
Phase II |
7002 |
Hematologic Malignancies -- newly diagnosed diffuse large B-cell lymphoma (DLBCL) |
30th May 2026 |
|
|
Concomitant Radiotherapy With Olaparib and Temozolomide |
Oral Abstract Session |
Phase IIa |
2005 |
Central Nervous System Tumors--unresectable high-grade glioma |
30th May 2026 |
|
|
Enzalutamide and Talazoparib |
Oral Abstract Session |
Phase II |
5006 |
Genitourinary Cancer -- metastatic hormone-naive prostate cancer (mHNPC) |
30th May 2026 |
|
|
Asandeuteritnib (TY-9591) |
Oral Abstract Session |
Phase II |
LBA2007 |
EGFR-mutated NSCLC patients with brain metastases |
30th May 2026 |
|
|
IO102-IO103 and nivolumab-relatlimab |
Rapid Oral Abstract Session |
Phase II |
9519 |
Melanoma/Skin Cancers--previously untreated, unresectable melanoma |
30th May 2026 |
|
|
Nivolumab and Ipilimumab |
Oral Abstract Session |
Phase II |
2502 |
Rare Tumors |
31st May 2026 |
|
|
Linperlisib +CHOP |
Oral Abstract Session |
Phase Ib/II |
7004 |
Hematologic Malignancies -- newly diagnosed peripheral T-cell lymphoma |
30th May 2026 |
|
|
GRWD5769 ± cemiplimab |
Oral Abstract Session |
Phase I/II |
2500 |
Solid tumors with anti-PD-1 resistance or MSS-CRC |
31st May 2026 |
|
|
PF-07799544 + PF-07799933 |
Rapid Oral Abstract Session |
Phase Ib |
9512 |
Melanoma/Skin Cancers--advanced BRAF-mutant melanoma |
30th May 2026 |
|
|
AZD3470 |
Oral Abstract Session |
Phase I |
7003 |
Hematologic Malignancies -- relapsed/refractory classic Hodgkin lymphoma |
30th May 2026 |
|
|
Cadonilimab or ivonescimab + axitinib |
Rapid Oral Abstract Session |
Phase Ib |
9516 |
Melanoma/Skin Cancers--metastatic mucosal melanoma |
30th May 2026 |
|
|
IOS-1002 + Pembrolizumab |
Oral Abstract Session |
Phase Ia |
2501 |
Re-sensitizing PD-1/PD-L1 relapsed/refractory solid tumors |
31st May 2026 |
|
|
Velzatinib (IDRX-42) |
Oral Abstract Session |
Phase I/Ib |
11501 |
Advanced gastrointestinal stromal tumors (GISTs) |
30th May 2026 |
Executive Summary
Leading companies, including Revolution Medicines, Pfizer, Akeso, and AstraZeneca and others, are anticipated to present pivotal Phase III and late-stage clinical data that could significantly influence future treatment landscapes and clinical practice.